You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)

    Not yet recruiting
    • Relapsed/Refractory Lymphoma
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Feb 2, 2023

    Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

    Recruiting
    • Lymphoma
    • CD70-targeting CAR-T cells
    • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
      China
    Jul 9, 2023

    Lymphoma, Solid Tumors Trial in Guangzhou (Mitoxantrone Hydrochloride Liposome)

    Recruiting
    • Lymphoma, Solid Tumors
    • Mitoxantrone Hydrochloride Liposome
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Nov 14, 2022

    Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

    Not yet recruiting
    • Lymphoma, B-Cell
    • +7 more
    • Adaptive Bridging Radiation Therapy (ABRT)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 16, 2023

    T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)

    Recruiting
    • T-lymphoblastic Lymphoma
    • +5 more
    • BCL2 Inhibitor plus IM2 regimen
    • Shanghai, Shanghai, China
      Shanghai General hospital,Shanghai Jiao Tong University School o
    Jan 10, 2023

    Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
    • +5 more
    • (no location specified)
    Dec 2, 2022

    Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed Trial in United States (MT-601)

    Recruiting
    • Non-Hodgkin Lymphoma, Adult
    • +3 more
    • Duarte, California
    • +3 more
    Apr 4, 2023

    Lymphoma Trial (6MW3211)

    Not yet recruiting
    • Lymphoma
    • (no location specified)
    Jul 2, 2022

    Relapsed/Refractory Lymphoma Trial in Chengdu (TQB2618 injection, Penpulimab injection)

    Recruiting
    • Relapsed/Refractory Lymphoma
    • TQB2618 injection
    • Penpulimab injection
    • Chengdu, Sichuan, China
      Sichuan Cancer Hospital
    Jun 1, 2022

    Relapsed/Refractory Lymphoma Trial in Shanghai (F527)

    Not yet recruiting
    • Relapsed/Refractory Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital Affiliated to Shanghai Jiaotong University Schoo
    Mar 14, 2022

    OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

    Not yet recruiting
    • OR Regimen Refractory Marginal Zone Lymphoma
    • obrutinib, rituximab
    • (no location specified)
    Nov 12, 2023

    Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

    Recruiting
    • Mantle Cell Lymphoma
    • Refractory Lymphoma
    • Boston, Massachusetts
    • +1 more
    Aug 8, 2022

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023

    Recurrent/Refractory Lymphoma Trial in Guiyang (Mitoxantrone Hydrochloride Liposome Injection)

    Completed
    • Recurrent/Refractory Lymphoma
    • Mitoxantrone Hydrochloride Liposome Injection
    • Guiyang, Guizhou, China
      Guizhou Cancer Hospita
    Dec 12, 2021

    Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
    • (no location specified)
    Sep 5, 2023

    Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

    Recruiting
    • Relapsed or Refractory CD19+ B-cell Lymphoma
    • +2 more
    • TBI-2001
    • +2 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jul 26, 2023

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

    Active, not recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • BEBT-908 for injection
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Oct 8, 2023

    Advanced Solid Tumor, Lymphoma, NSCLC Trial in Chaoyang, Cangzhou, Tianjin (BPI-371153)

    Not yet recruiting
    • Advanced Solid Tumor
    • +3 more
    • Chaoyang, Beijing, China
    • +3 more
    Jun 15, 2022

    Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • infusion of JY231 injection
    • Guangzhou, Guangdong, China
      Guangdong Second Provincial General Hospital
    Sep 17, 2023

    Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

    Recruiting
    • Peripheral T Cell Lymphoma
    • +2 more
    • Chidamide combined with Duvillisib
    • Xiamen, Fujian, China
      The First Affiliated Hosptial of Xiamen University
    Nov 28, 2023

    Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Relmacabtagene Autoleucel Injection
    • (no location specified)
    Apr 13, 2023

    Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

    Not yet recruiting
    • Relapsed/Refractory B-Cell Lymphoma
    • (no location specified)
    Jul 10, 2023

    Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

    Not yet recruiting
    • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
    • (no location specified)
    Jun 28, 2023

    B-cell Non Hodgkin Lymphoma, Richter's Transformation Trial in United States (Cosibelimab, Cosibelimab + Ublituximab +

    Terminated
    • B-cell Non Hodgkin Lymphoma
    • Richter's Transformation
    • Cosibelimab
    • Cosibelimab + Ublituximab + Bendamustine combination
    • Huntsville, Alabama
    • +8 more
    Aug 19, 2022